real-time news and commentary for investors
Wednesday, Sep 26
2012, 10:24 AM
Depomed ([[DEPO] +1.4%) has filed a suit in a federal court in Washington, D.C., seeking an...
Depomed ([[DEPO] +1.4%) has filed a suit in a federal court in Washington, D.C., seeking an order to require the FDA to grant market exclusivity for Gralise, it's treatment for post-herpetic neuralgia under the orphan-drug designation. The drug received an orphan drug designation in November 2010, and was approved in January 2011. Since its approval, the FDA has not granted orphan drug exclusivity to Gralise, and DEPO claims it's entitled to exclusivity under the law.